Iovance CFO Jean-Marc Bellemin resigns effective July 10, 2025

IOVANCE BIOTHERAPEUTICS, INC.

Jean-Marc Bellemin, CFO and principal financial & accounting officer, resigns effective July 10, 2025.
No replacement named; company states departure is to pursue other opportunities.
Frederick G. Vogt serves as Interim CEO and President; CFO role remains unfilled.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jean-Marc Bellemin

Chief Financial Officer

IOVA · IOVANCE BIOTHERAPEUTICS, INC.

Effective: 2025-07-10
Filed: Jun 13, 2025 23:59 UTC

On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer and principal financial and accounting officer of Iovance Biotherapeutics, Inc. (the “Company”), provided the Company with written notice under his Executive Employment Agreement, dated November 23, 2020, that he would resign from the Company, effective July 10, 2025, to pursue other opportunities.

Source: SEC EDGAR

accession 0001104659-25-059464

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.